An optimization model for reducing typhoid cases in developing countries without increasing public spending

Vaccine

Volumn 27, Issue 10, 2009, Pages 1609-1621

  Lauria, Donald T ^a   Maskery, Brian ^a   Poulos, Christine ^b   Whittington, Dale ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Optimization; Policy; Typhoid vaccine; User charges; Vaccine demand

Indexed keywords

TYPHOID VACCINE;

ARTICLE; CONSUMER; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DRUG EFFICACY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH SURVEY; MASS IMMUNIZATION; MATHEMATICAL MODEL; MONTE CARLO METHOD; MORBIDITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOUTH ASIA; SOUTHEAST ASIA; TYPHOID FEVER; VACCINATION;

ADULT; ASIA, SOUTHEASTERN; CHILD; COMMERCE; DEVELOPING COUNTRIES; HUMANS; IMMUNITY, HERD; MASS IMMUNIZATION; MODELS, ECONOMIC; MONTE CARLO METHOD; POLYSACCHARIDES, BACTERIAL; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 60349127223     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.032     Document Type: Article

References (35)

1. Acosta C., Galindo C., Deen J., Ochiai R., Lee H., von Seidlein L., et al. Vaccines against cholera, typhoid fever, and shigellosis for developing countries. Expert Opinion on Biological Therapy 12 (2004) 1939-1951
2. DeRoeck D., Clemens J.D., Nyamete A., and Mahoney R.T. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23 (2005) 2762-2774
3. Beutels P., Edmunds W.J., Antoñanzas F., Wit G.A.D., Evans D., Feilden R., et al. Economic evaluation of vaccination programmes. A consensus statement focusing on viral hepatitis. Pharmacoeconomics 20 1 (2002) 1-7
4. Beutels P., Thiry N., and Dammea P.V. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25 (2007) 1355-1367
5. Fox-Rushby J.A., and Hanson K. Calculating and presenting disability life years (DALYs) in cost effectiveness analysis. Health Policy and Planning 16 3 (2001) 326-331
6. Szucs T.D. Health economic research on vaccinations and immunization practices-an introductory primer. Vaccine 23 (2005) 2095-2103
7. Boulier B.L., Datta T.S., and Goldfarb R.S. Vaccination externalities. The BE Journal of Economic Analysis & Policy 7 1 (2007) [Article 23]
8. Brito D.L., Sheshinski E., and Intriligator M.D. Externalities of compulsory vaccinations. Journal of Public Economics 45 (1991) 69-90
9. Cook J., Jeuland M., Maskery B., Lauria D., Sur D., Clemens J., et al. Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. Journal of Policy Analysis and Management 28 1 (2009) 6-28
10. Francis P.J. Dynamic epidemiology and the market for vaccinations. Journal of Public Economics 63 (1997) 383-406
11. Francis P.J. Optimal tax/subsidy combinations for the flu season. Journal of Economic Dynamics & Control 28 (2004) 2037-2054
12. Becker N., and Starczak D. Optimal vaccination strategies for a community of households. Mathematical Biosciences 139 (1997) 117-132
13. Patel R., Longini Jr. I.M., and Halloran M.E. Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. Journal of Theoretical Biology 234 (2005) 201-212
14. Cropper M.L., Haile M., Lampietti J., Poulos C., and Whittington D. The demand for a malaria vaccine: evidence from Ethiopia. Journal of Development Economics 75 (2004) 303-318
15. Hsu H.-C., Lin R.S., Tung T.H., and Chen T.H.H. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 21 (2003) 3982-3987
16. Suraratdecha C., Ainsworth M., Tangcharoensathien V., and Whittington D. The private demand for an AIDS vaccine in Thailand. Health Policy and Planning 71 (2005) 271-287
17. Whittington D., Matsui O., Frieberger J., Houtven G.V., and Pattanayak S. Private demand for an HIV/AIDS vaccine: Evidence from Guadalajara, Mexico. Vaccine 20 (2002) 2585-2591
18. Canh D.G., Whittington D., Thoa L.T.K., Utomo N., Hoa N.T., Poulos C., et al. Household demand for typhoid fever vaccines in Hue, Vietnam: implications for immunization programs. Health Policy and Planning 21 3 (2006) 241-255
19. Cook J., Johnson F.R., Nyamete A., Canh D.G., and Whittington D. Reliability of stated preferences for vaccines with time to think. Economic Inquiry 45 1 (2006) 100-114
20. Whittington D., Sur D., Cook J., Chatterjee S., Maskery B., Lahiri M., et al. Private Demand for Cholera and Typhoid vaccines in Kolkata, India. World Development 37 2 (2009) 399-409
21. Islam Z., Maskery B., Nyamete A., Horowitz M., Yunus M., and Whittington D. Private demand for cholera vaccines in rural Bangladesh. Health Policy 85 (2008) 184-195
22. Kim D., Canh D.G., Poulos C., Thoa L.T.K., Cook J., Hoa N.T., et al. Private demand for cholera vaccines in Hue, Vietnam. Value in Health 11 1 (2008) 119-128
23. Lucas M.E.S., Jeuland M., Deen J., Lazaro N., MacMahon M., Nyamete A., et al. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 25 (2007) 2599-2609
24. Bhan M.K., Bahl R., and Bhatnagar S. Typhoid and paratyphoid fever. Lancet 366 (2005) 749-762
25. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., et al. Typhoid fever in children aged less than 5 years. The Lancet 354 (1999) 734-737
26. Ochiai R.L., Acosta C.J., Danovaro-Holliday M.C., Baiqing D., Bhattacharya S.K., Agtini M.D., et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bulletin of the World Health Organization 86 (2008) 260-268
27. Bahl R., Sinha A., Poulos C., Whittington D., Sazawal S., Kumar R., et al. Costs of illness due to typhoid fever in Indian urban slum community: implications for vaccination policy. Journal of Health, Population and Nutrition 22 (2004) 304-310
28. Poulos C, Riewpaiboon A, Stewart JF, Nyamete A, Guh S, Clemens J, et al. Cost of illness due to typhoid fever in study sites in five Asian countries. IVI Report. Seoul, Korea, 2008.
29. Cavailler P., Lucas M., Perroud V., McChesney M., Ampuero S., Guerin P.J., et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 24 22 (2006) 4890-4895
30. Stewart JF. Vaccination cost: Vi vaccine In Vietnam, India, and Indonesia. Report to the International Vaccine Institute. Seoul, Korea, 2005.
31. Thiem V.D., Hossain M.M., Son N.D., Hoa N.T., Rao M.R., Canh D.G., et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. Journal of Health, Population and Nutrition 21 4 (2003) 304-308
32. Anderson R.M. Modern vaccines: immunization and herd immunity. The Lancet 335 8690 (1990) 641-645
33. Anderson R.M., and May R.M. Vaccination and herd immunity to infectious diseases. Nature 318 28 (1985) 323-329
34. Gordis L. Epidemiology (2000), W.B. Saunders Co., Philadelphia, PA
35. Fine P.E.M. Herd immunity: History, theory and practice. Epidemiologic Reviews 15 2 (1993) 265-302